CGT recognizes that successful product development requires a complex array of clinical, manufacturing and business expertise and substantial financial resources. Therefore, CGT intends to explore business relationships with larger companies that have resources to expedite CG201’s late-stage clinical testing and product introduction. CGT will consider clinical research collaborations, licensing agreements or a merger.

The company’s long-term mission is to bring a continuing series of FDA approvals for CG201 against various types of cancer, as well as full development of an immunocontraceptive useful in the developing world, while advance its mission to become a world leader in controling hCG’s effects in human health and disease.